Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 164

Similar articles for PubMed (Select 10632283)

1.
2.

Antiretroviral hepatotoxicity in human immunodeficiency virus-infected patients.

Hernandez LV, Gilson I, Jacobson J, Affi A, Puetz TR, Dindzans VJ.

Aliment Pharmacol Ther. 2001 Oct;15(10):1627-32.

3.

Incidence of and risk factors for severe hepatotoxicity of nelfinavir-containing regimens among HIV-infected patients with chronic hepatitis C.

Mira JA, Macías J, Girón-González JA, Merino D, González-Serrano M, Jiménez-Mejías ME, Caballero-Granado FJ, Torre-Cisneros J, Terrón A, Becker MI, Gómez-Mateos J, Arizcorreta-Yarza A, Pineda JA; Grupo Andaluz Para el Estudio de las Enfermedades Infecciosas (GAEI).

J Antimicrob Chemother. 2006 Jul;58(1):140-6. Epub 2006 May 23.

4.

Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection.

den Brinker M, Wit FW, Wertheim-van Dillen PM, Jurriaans S, Weel J, van Leeuwen R, Pakker NG, Reiss P, Danner SA, Weverling GJ, Lange JM.

AIDS. 2000 Dec 22;14(18):2895-902.

PMID:
11153671
5.

Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir.

Sulkowski MS, Mehta SH, Chaisson RE, Thomas DL, Moore RD.

AIDS. 2004 Nov 19;18(17):2277-84.

PMID:
15577540
6.

Pretreatment of chronic active hepatitis C in patients coinfected with HIV and hepatitis C virus reduces the hepatotoxicity associated with subsequent antiretroviral therapy.

Uberti-Foppa C, De Bona A, Morsica G, Galli L, Gallotta G, Boeri E, Lazzarin A.

J Acquir Immune Defic Syndr. 2003 Jun 1;33(2):146-52.

PMID:
12794546
7.

Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections.

Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD.

Hepatology. 2002 Jan;35(1):182-9.

PMID:
11786975
8.

[Safety of atazanavir in patients with HIV and hepatitis B and/or C virus coinfection].

Rivero A, Camacho A, Pérez-Camacho I, Torre-Cisneros J.

Enferm Infecc Microbiol Clin. 2008 Dec;26 Suppl 17:45-8. doi: 10.1016/S0213-005X(08)76620-5. Review. Spanish.

PMID:
20116617
9.

Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy.

Martínez E, Blanco JL, Arnaiz JA, Pérez-Cuevas JB, Mocroft A, Cruceta A, Marcos MA, Milinkovic A, García-Viejo MA, Mallolas J, Carné X, Phillips A, Gatell JM.

AIDS. 2001 Jul 6;15(10):1261-8.

PMID:
11426070
10.

Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Cvetkovic RS, Goa KL.

Drugs. 2003;63(8):769-802. Review.

PMID:
12662125
11.

Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients.

Labarga P, Soriano V, Vispo ME, Pinilla J, Martin-Carbonero L, Castellares C, Casado R, Maida I, Garcia-Gasco P, Barreiro P.

J Infect Dis. 2007 Sep 1;196(5):670-6. Epub 2007 Jul 13.

12.

Hepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in Cameroon.

Mbougua JB, Laurent C, Kouanfack C, Bourgeois A, Ciaffi L, Calmy A, Gwet H, Koulla-Shiro S, Ducos J, Mpoudi-Ngolé E, Molinari N, Delaporte E.

BMC Public Health. 2010 Mar 1;10:105. doi: 10.1186/1471-2458-10-105.

13.

Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: the role of hepatitis B and C virus infection.

Aceti A, Pasquazzi C, Zechini B, De Bac C; LIVERHAART Group.

J Acquir Immune Defic Syndr. 2002 Jan 1;29(1):41-8.

PMID:
11782588
14.

Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine.

Macías J, Castellano V, Merchante N, Palacios RB, Mira JA, Sáez C, García-García JA, Lozano F, Gómez-Mateos JM, Pineda JA.

AIDS. 2004 Mar 26;18(5):767-74.

PMID:
15075511
15.

Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001.

Law WP, Dore GJ, Duncombe CJ, Mahanontharit A, Boyd MA, Ruxrungtham K, Lange JM, Phanuphak P, Cooper DA.

AIDS. 2003 Oct 17;17(15):2191-9.

PMID:
14523276
16.

Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy.

Wit FW, Weverling GJ, Weel J, Jurriaans S, Lange JM.

J Infect Dis. 2002 Jul 1;186(1):23-31. Epub 2002 Jun 14.

17.

Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection.

Aranzabal L, Casado JL, Moya J, Quereda C, Diz S, Moreno A, Moreno L, Antela A, Perez-Elias MJ, Dronda F, Marín A, Hernandez-Ranz F, Moreno A, Moreno S.

Clin Infect Dis. 2005 Feb 15;40(4):588-93. Epub 2005 Jan 21.

18.

Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients.

Torti C, Costarelli S, De Silvestri A, Quiros-Roldan E, Lapadula G, Cologni G, Paraninfo G, Castelnuovo F, Puoti M, Carosi G; BHCC Study Group.

Drug Saf. 2007;30(12):1161-9.

PMID:
18035868
19.

Incidence and risk factors for chronic elevation of alanine aminotransferase levels in HIV-infected persons without hepatitis b or c virus co-infection.

Kovari H, Ledergerber B, Battegay M, Rauch A, Hirschel B, Foguena AK, Vernazza P, Bernasconi E, Mueller NJ, Weber R.

Clin Infect Dis. 2010 Feb 15;50(4):502-11. doi: 10.1086/649922.

20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk